Moreover, CD45RA−FOXP3high CD4+ effector regulatory T cells (eTreg) were reduced in tumor infiltrates, and the VEGF-dependent proliferation of VEGFR2+ eTreg could be blocked by ramucirumab [77]. This evidence concerns the gene CD4 and neoplasm.